OGIVRI 150 mg/7.4mL
trastuzumab · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Mylan Institutional LLC
No Recall History
Plain English
OGIVRI is a injection, powder, lyophilized, for solution containing trastuzumab at 150 mg/7.4mL, taken intravenous. Manufactured by Mylan Institutional LLC.
Key Facts
- Brand Name
- OGIVRI
- Generic Name
- trastuzumab
- NDC Code (Product)
67457-991- Manufacturer
- Mylan Institutional LLC
- Strength
- 150 mg/7.4mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761074
- Marketing Start
- 11/29/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is OGIVRI used for?
OGIVRI contains trastuzumab. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is OGIVRI a controlled substance?
OGIVRI is not classified as a controlled substance by the DEA.
What is the generic name for OGIVRI?
The generic name for OGIVRI is trastuzumab. There are 8 other brand versions of trastuzumab.
What is the NDC code for OGIVRI 150 mg/7.4mL?
The NDC (National Drug Code) for OGIVRI 150 mg/7.4mL is 67457-991, listed by Mylan Institutional LLC.